Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Telix Pharmaceuticals [TLX.AX]

Exchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated31 May 2024 @ 02:10
25% discount on Stockinvest.us - Use code: Podcast

15.31% $ 18.15

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 02:10):
Profile picture for Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States...

Stats
Today's Volume 3.54M
Average Volume 1.20M
Market Cap 6.06B
EPS $0 ( 2024-02-21 )
Next earnings date ( $0 ) 2024-08-21
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 907.50
ATR14 $0.0260 (0.14%)

Volume Correlation

Long: -0.03 (neutral)
Short: -0.78 (moderate negative)
Signal:(74.685) Neutral

Telix Pharmaceuticals Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Telix Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.03
( neutral )
The country flag -0.12
( neutral )
The country flag 0.00
( neutral )
The country flag -0.16
( neutral )
The country flag -0.13
( neutral )
The country flag -0.13
( neutral )

Telix Pharmaceuticals Financials

Annual 2023
Revenue: $496.66M
Gross Profit: $308.50M (62.12 %)
EPS: $0.0163
FY 2023
Revenue: $496.66M
Gross Profit: $308.50M (62.12 %)
EPS: $0.0163
FY 2022
Revenue: $160.10M
Gross Profit: $29.34M (18.32 %)
EPS: $-0.340
FY 2021
Revenue: $4.90M
Gross Profit: $2.35M (47.98 %)
EPS: $-0.313

Financial Reports:

No articles found.

Telix Pharmaceuticals Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.2740831375122 seconds
Number of API calls: 2
Number of DB calls: 8